XFLH Capital Corporation (XFLH) has signed a non-binding letter of intent for a proposed business combination with Renogen Biolab Inc., a Canadian health service provider specializing in molecular capabilities such as DNA services, vector engineering, and protein expression.
The Letter of Intent sets out that both parties will use their reasonable best efforts to negotiate and execute definitive agreements for the proposed transaction as soon as practicable. Each side will provide the other and its representatives with reasonable access to information to conduct due diligence. XFLH Capital is a Cayman Islands blank check company formed to pursue mergers, stock exchanges, asset acquisitions, stock purchases, reorganizations, or similar business combinations.
XFLH Capital Corporation (NYSE: XFLH) announced that, effective Monday, March 9, 2026, holders of Units from its IPO may separately trade the underlying securities. Each Unit contains one ordinary Share and one Right to receive 1/7th of a Share upon a business combination.
Shares and Rights separated from Units will trade under XFLH and XFLHR, while non-separated Units continue trading as XFLHU. A Form S-1 (333-290588) was declared effective by the SEC on January 30, 2026. Holders must contact the transfer agent to separate Units.
XFLH Capital Corporation (NYSE:XFLHU) closed a $100.0 million initial public offering on February 13, 2026, selling 10,000,000 units at $10.00 each. Each unit comprises one ordinary share and one right to receive 1/7 of a share upon an initial business combination.
The units began trading February 12, 2026 under XFLHU; shares and rights are expected to trade separately as XFLH and XFLHR once separated. The underwriter has a 45-day option to purchase up to 1,500,000 additional units to cover over-allotments. Maxim Group acted as sole book-running manager.